- Home
- NCZ vs SNN Comparison
NCZ vs SNN Comparison
Compare NCZ & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCZ | SNN |
|---|---|---|
| Founded | 2003 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance Companies | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.7M | 14.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NCZ | SNN |
|---|---|---|
| Price | $14.18 | $32.35 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $36.25 |
| AVG Volume (30 Days) | 48.6K | ★ 781.6K |
| Earning Date | 01-01-0001 | 03-02-2026 |
| Dividend Yield | ★ 12.16% | 2.28% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $7.19 |
| Revenue Next Year | N/A | $5.36 |
| P/E Ratio | ★ N/A | $64.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.23 | $23.91 |
| 52 Week High | $14.99 | $38.79 |
Technical Indicators
Market Signals| Indicator | NCZ | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 40.16 | 35.57 |
| Support Level | $13.59 | $32.15 |
| Resistance Level | $14.25 | $33.89 |
| Average True Range (ATR) | 0.22 | 0.69 |
| MACD | -0.04 | -0.31 |
| Stochastic Oscillator | 24.38 | 7.89 |
Price Performance
Historical ComparisonAbout NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.